Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

ClinicalTrials.gov ID: NCT00123890

Public ClinicalTrials.gov record NCT00123890. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Screening Protocol to Determine Eligibility for One of Three Phase III Treatment Studies Evaluating the Efficacy and Safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 Infected, Treatment-experienced Subjects With Drug-resistant Virus or an Observational Study.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine eligibility for one of three treatment studies of the CCR5 antagonist GW873140 or an observational study without GW873140. No investigational treatment will be administered through this study.

Study identification

NCT ID
NCT00123890
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
Not listed

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2005 (Type not available)
Primary completion
Oct 2005 (Actual)
Completion
Oct 2005 (Actual)
Last update posted
Mar 29, 2011

2005

United States locations

U.S. sites
34
U.S. states
19
U.S. cities
33
Facility City State ZIP Site status
GSK Investigational Site Tucson Arizona 85745 —
GSK Investigational Site Laguna Beach California 92651 —
GSK Investigational Site Long Beach California 90813 —
GSK Investigational Site Los Angeles California 90046 —
GSK Investigational Site Oakland California 94609 —
GSK Investigational Site Tarzana California 30342 —
GSK Investigational Site Glastonbury Connecticut 06033 —
GSK Investigational Site Norwalk Connecticut 06851 —
GSK Investigational Site Washington D.C. District of Columbia 20009 —
GSK Investigational Site Fort Lauderdale Florida 33308 —
GSK Investigational Site Hollywood Florida 33020 —
GSK Investigational Site Oakland Park Florida 33334 —
GSK Investigational Site Orlando Florida 32804 —
GSK Investigational Site Plantation Florida 33317 —
GSK Investigational Site Tampa Florida 33607 —
GSK Investigational Site Atlanta Georgia 30339 —
GSK Investigational Site Chicago Illinois 60657 —
GSK Investigational Site New Orleans Louisiana 70127-0800 —
GSK Investigational Site Baltimore Maryland 21201 —
GSK Investigational Site Boston Massachusetts 02215 —
GSK Investigational Site Minneapolis Minnesota 55404 —
GSK Investigational Site Las Vegas Nevada 89102 —
GSK Investigational Site East Orange New Jersey 07018 —
GSK Investigational Site Newark New Jersey 07102 —
GSK Investigational Site New York New York 10014 —
GSK Investigational Site Akron Ohio 44304 —
GSK Investigational Site Portland Oregon 97209 —
GSK Investigational Site Portland Oregon 97219 —
GSK Investigational Site Austin Texas 78746 —
GSK Investigational Site Dallas Texas 75246 —
GSK Investigational Site Houston Texas 77027 —
GSK Investigational Site Hampton Virginia 23666 —
GSK Investigational Site Lynchburg Virginia 24501 —
GSK Investigational Site Spokane Washington 99204 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00123890, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 29, 2011 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00123890 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →